Arvest Investments Inc. Cuts Stock Holdings in Pfizer Inc. (NYSE:PFE)

Arvest Investments Inc. lessened its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 47.1% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 48,765 shares of the biopharmaceutical company's stock after selling 43,356 shares during the period. Arvest Investments Inc.'s holdings in Pfizer were worth $1,236,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. Coerente Capital Management boosted its stake in Pfizer by 1.3% in the 1st quarter. Coerente Capital Management now owns 601,217 shares of the biopharmaceutical company's stock worth $15,235,000 after purchasing an additional 7,539 shares during the period. Thompson Investment Management Inc. lifted its holdings in shares of Pfizer by 1.8% in the first quarter. Thompson Investment Management Inc. now owns 410,845 shares of the biopharmaceutical company's stock worth $10,411,000 after buying an additional 7,381 shares in the last quarter. Alpha Omega Wealth Management LLC boosted its position in shares of Pfizer by 30.6% during the first quarter. Alpha Omega Wealth Management LLC now owns 179,570 shares of the biopharmaceutical company's stock worth $4,550,000 after acquiring an additional 42,083 shares during the last quarter. Capital Advisory Group Advisory Services LLC grew its stake in Pfizer by 19.6% during the first quarter. Capital Advisory Group Advisory Services LLC now owns 13,154 shares of the biopharmaceutical company's stock valued at $333,000 after acquiring an additional 2,156 shares in the last quarter. Finally, Focus Financial Network Inc. increased its holdings in Pfizer by 1.3% in the 1st quarter. Focus Financial Network Inc. now owns 47,522 shares of the biopharmaceutical company's stock valued at $1,204,000 after acquiring an additional 607 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on PFE shares. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target for the company. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, UBS Group boosted their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Trading Down 1.5%

NYSE PFE traded down $0.36 during trading on Friday, hitting $24.48. The stock had a trading volume of 36,015,012 shares, compared to its average volume of 41,099,737. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The stock has a 50 day simple moving average of $23.01 and a 200 day simple moving average of $24.97. The stock has a market capitalization of $139.17 billion, a price-to-earnings ratio of 17.37, a P/E/G ratio of 0.64 and a beta of 0.57. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period in the previous year, the firm earned $0.82 earnings per share. The business's revenue was down 7.8% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.03%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.